SAN DIEGO, CA – August 18, 2017 –CureMatch, a digital health company focusing on personalized medicine and combination therapy in oncology, today announced that it has closed its bridge round to Series A financing. CureMatch is the only company to offer a data-driven report that scores combinations of cancer drugs that are tailored for individual patients. The report is generated using CureMatch’s Decision Support System, which analyzes millions of cancer treatment options with its proprietary algorithms and evidence-based, custom-curated databases of genomics and proteomics information.
This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.
Otherwise, you will be redirected to the institutional part of this website.
Thank you for your understanding.